Abstract：
:Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing vascular endothelial growth factor. Adverse events resulting from its use include gastrointestinal perforation, wound-healing complications, hemorrhage, and arterial thromboembolism. We present a case of a 67-year-old man who developed Fournier's gangrene during treatment with bevacizumab 4 months after completing mFOLFOX6 (5-FU/leucovorin/oxaliplatin) for CRC. Other than bevacizumab, the patient had no medications and had no medical conditions that would predispose to Fournier's gangrene.
journal_name
Clin Colorectal Cancerjournal_title
Clinical colorectal cancerauthors
Gamboa EO,Rehmus EH,Haller Ndoi
10.3816/CCC.2010.n.008subject
Has Abstractpub_date
2010-01-01 00:00:00pages
55-8issue
1eissn
1533-0028issn
1938-0674pii
S1533-0028(11)70034-2journal_volume
9pub_type
杂志文章abstract：UNLABELLED:Two identical randomized controlled trials designed to optimize adjuvant treatment of colon cancer (CC) (n =855) and rectal cancer (RC) (n = 796) were performed. Long-term evaluation confirmed that the addition of folinic acid (FA) to 5-fluorouracil (5-FU) improved 7-year overall survival (OS) in CC but not ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.clcc.2012.07.005
更新日期：2013-03-01 00:00:00
abstract：:Hepatic colorectal metastases present a challenging problem in patients with recurrent colorectal cancer. Twenty percent of patients with recurrence will have liver metastases as a component of their disease, and only 10% of these patients will have isolated liver metastases that are resectable. Although systemic chem...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2003.n.010
更新日期：2003-05-01 00:00:00
abstract：BACKGROUND:Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases rema...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2017.10.002
更新日期：2018-03-01 00:00:00
abstract：PURPOSE:American Society of Clinical Oncology (ASCO) guidelines define high-risk prognostic features (HRFs) in stage II colon cancer and recommend limiting adjuvant chemotherapy to patients with HRFs. We evaluated the extent to which HRFs influenced decisions on adjuvant chemotherapy before and after publication of the...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：
更新日期：2009-04-01 00:00:00
abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.clcc.2018.02.004
更新日期：2018-06-01 00:00:00
abstract：BACKGROUND:Recent trends have identified increasing number of young individuals with rectal and colon cancers. These individuals, who are younger than 50 years old, in most instances would not meet screening guidelines. We aimed to report the characteristics and trend of the rising proportion of young individuals being...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.10.002
更新日期：2019-03-01 00:00:00
abstract：BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2019.09.002
更新日期：2020-06-01 00:00:00
abstract：OBJECTIVE:The purposes of this study were to confirm the definite metastasis and micrometastasis rate of upward and lateral lymph nodes of mid-to-low rectal cancer at stage II and stage III, and to evaluate the feasibility and safety of laparoscopic radical correction combined with extensive lymphadenectomy and pelvic ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2011.03.025
更新日期：2011-09-01 00:00:00
abstract：:The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clcc.2015.05.006
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2015.08.003
更新日期：2016-03-01 00:00:00
abstract：INTRODUCTION:Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. METHODS:C...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clcc.2017.03.003
更新日期：2017-12-01 00:00:00
abstract：BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2020.05.011
更新日期：2020-09-01 00:00:00
abstract：BACKGROUND:Anterior resection syndrome (ARS) is common after sphincter-saving surgery for rectal cancer. It includes changes in the frequency and urgency of bowel movements and fecal incontinence. The therapeutic efficacy of biofeedback on ARS is unclear. We sought to evaluate the effectiveness of biofeedback therapy i...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2015.11.002
更新日期：2016-09-01 00:00:00
abstract：:Despite an armamentarium that is wide in range, scope of action, and target, chemotherapy has limited success in colorectal cancer (CRC). Novel approaches are needed to overcome tumor barriers to chemotherapy that includes an abnormal tumor vasculature constituting a poor drug delivery system. We have previously shown...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2009.n.025
更新日期：2009-07-01 00:00:00
abstract：INTRODUCTION:Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS:T...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2016.08.003
更新日期：2017-09-01 00:00:00
abstract：BACKGROUND:The safety of bevacizumab in older mCRC patients is poorly understood. The purpose of this analysis was to determine the prevalence, incidence, and risk factors for treatment-related AEs in older bevacizumab recipients. PATIENTS AND METHODS:Patients age ≥65 were identified from SEER-Medicare and categorized...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2012.11.004
更新日期：2013-09-01 00:00:00
abstract：PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/ccc.2005.n.021
更新日期：2005-07-01 00:00:00
abstract：BACKGROUND:The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS:We retros...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2017.03.019
更新日期：2017-12-01 00:00:00
abstract：BACKGROUND:Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin. A combination regimen using all 4 agents could potentially increase response rates in CRC. PATIENTS AND METHODS:A multicenter phase II trial of oxaliplatin ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CCC.2007.n.017
更新日期：2007-05-01 00:00:00
abstract：BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2020.08.003
更新日期：2020-08-19 00:00:00
abstract：:Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect thei...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clcc.2014.12.002
更新日期：2015-03-01 00:00:00
abstract：:Adult intussusception is a rare occurrence and, unlike in childhood, is usually associated with an underlying tumor. Although computed tomography (CT) imaging can identify an intussusception and point toward a cause, diagnosis is challenging if it is only intermittent. When an intussusception presents in the context o...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2008.n.028
更新日期：2008-05-01 00:00:00
abstract：BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.08.002
更新日期：2018-12-01 00:00:00
abstract：:Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States. Despite excellent prognosis for early stage disease, 5-year survival rates in metastatic disease remain low. A small subset of CRC is defined by a deficiency in mismatch repair (dMMR) resulting in high levels of micro...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clcc.2020.02.002
更新日期：2020-06-01 00:00:00
abstract：:Thymidylate synthase (TS) expression has been identified as an important predictor of response to 5-fluorouracil (5-FU). However, there is relatively little information on the heterogeneity of TS mRNA expression between primary and metastatic tumors, as well as differential expression of TS mRNA in metastatic sites. I...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2001.n.017
更新日期：2001-11-01 00:00:00
abstract：BACKGROUND:We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer. MATERIALS AND METHODS:We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clcc.2018.03.007
更新日期：2018-09-01 00:00:00
abstract：:Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2004.s.009
更新日期：2004-10-01 00:00:00
abstract：:The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease. Total mesorectal excision has led to lower local recurrence rates, and, if properly performed, may make adjuvant radiation unnecessary for certain stage II and III patients, such as T3 N0 pati...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2003.n.002
更新日期：2003-02-01 00:00:00
abstract：:This article reviews the current status of the topoisomerase I (top I) inhibitors in the treatment of gastrointestinal (GI) malignancies. We focus on oral drug administration, the mode of administration that is generally preferred by patients with cancer. However, the great majority of the studies have been performed ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2004.n.017
更新日期：2004-09-01 00:00:00
abstract：BACKGROUND:The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In the context of a prospective single-arm trial (NC...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clcc.2018.06.003
更新日期：2018-12-01 00:00:00
